Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | PF-07257876 |
Synonyms | |
Therapy Description |
PF-07257876 is a bispecific antibody that targets CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD47 and PD-L1 (CD274) (NCI Thesaurus). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
PF-07257876 | PF 07257876|PF07257876 | CD47 Antibody 30 PD-L1 Inhibitor 13 | PF-07257876 is a bispecific antibody that targets CD47 and PD-L1 (CD274), which may lead to increased phagocytosis and enhanced cytotoxic T-lymphocyte (CTL) response against tumor cells expressing CD47 and PD-L1 (CD274) (NCI Thesaurus). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04881045 | Phase I | PF-07257876 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | Completed | USA | ESP | 0 |